Welcome to our dedicated page for Zimmer Biomet Holdings news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet Holdings stock.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) is a preeminent global leader in musculoskeletal healthcare. Headquartered in Warsaw, Indiana, Zimmer Biomet has been at the forefront of advancing bone and joint health for nearly 90 years. The company designs, manufactures, and markets a comprehensive range of orthopedic implants and surgical equipment, addressing joint reconstruction, bone repair, sports medicine, spine, and dental reconstruction. Its innovative product portfolio includes the ROSA® Robotics systems for knee, hip, and shoulder replacements, and the TMINI Miniature Robotic System for total knee arthroplasty.
Zimmer Biomet's latest endeavors include the establishment of a dedicated Health Equity division in 2023, which aims to integrate health equity into the company's core strategies and operations. This division has already made significant strides by assembling a strategic advisory board and developing the Community Centered Care (C3) framework to increase patient access to quality care in underserved communities.
In addition, Zimmer Biomet has recently partnered with top pickleball organizations in the U.S., underscoring its commitment to joint health and well-being for the growing community of pickleball players. The company also announced a strategic alliance with CBRE Group, Inc. to expand orthopedic ambulatory surgery centers across the country, and a collaboration with RevelAi Health to commercialize AI-powered engagement solutions aimed at advancing value-based orthopedic care and health equity.
Financially, Zimmer Biomet has demonstrated robust performance, with first-quarter 2024 net sales amounting to $1.889 billion, a 3.2% year-over-year increase. The company continues to focus on innovation, operational excellence, and strategic partnerships to drive growth and enhance shareholder value. For more information, visit www.zimmerbiomet.com or follow them on LinkedIn and Twitter.
On December 1, 2020, ZBH announced the completion of its acquisition of A&E Medical Corporation for $150 million in cash at closing and $100 million payable in 2021. This acquisition enhances Zimmer Biomet's portfolio with sternal closure devices, including sutures and rigid fixation systems. The deal is expected to have an immaterial impact on net earnings for 2020. The global sternal closure market is growing at a high single-digit percentage rate annually, indicating potential for expanded revenue through this integration.
Zimmer Biomet Holdings (NYSE: ZBH) announced that President and CEO Bryan Hanson and CFO Suky Upadhyay will present at the 2020 Evercore ISI HealthCONx Conference on December 1, 2020, at 10:30 a.m. ET. Upadhyay will also present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2, 2020, at 11:00 a.m. ET. Live webcasts can be accessed via the Investor Relations website and will be archived for future viewing. Founded in 1927, Zimmer Biomet is a leader in musculoskeletal healthcare, providing innovative solutions for orthopedic care globally.
Zimmer Biomet reported third quarter 2020 net sales of $1.929 billion, a 2.0% increase year-over-year. Net earnings were $242.5 million, with diluted earnings per share at $1.16, down 44.2% compared to last year. Adjusted EPS rose by 2.3% to $1.81. The company completed two acquisitions totaling $80 million, enhancing its product offerings in the operating room and arthroscopy markets. However, they face ongoing uncertainties due to COVID-19, impacting guidance for future quarters.
Zimmer Biomet announced preliminary results from a clinical trial evaluating its mymobility platform with Apple Watch. Presented at the AAHKS annual meeting, the trial involved 448 patients undergoing knee arthroplasty. Results showed mymobility yielded similar early outcomes compared to traditional care. Notably, mymobility patients required significantly fewer physical therapy visits (p<0.0001) and reported lower emergency visits and readmission rates, although these were not statistically significant. The platform aims to enhance remote care management while potentially lowering overall healthcare costs.
Zimmer Biomet, a leader in musculoskeletal healthcare, will present at the Stifel Virtual Healthcare Conference on November 17 at 11:20 a.m. ET. The presentation will be led by President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay. Investors can access the live webcast at Zimmer Biomet's Investor Relations website, where the presentation will also be archived for replay. Founded in 1927, Zimmer Biomet designs and markets a broad range of orthopedic and surgical products worldwide.
Zimmer Biomet Holdings (NYSE: ZBH) announced that Liane Teplitsky, VP and General Manager of Worldwide Robotics, will present at the SVB Leerink CybeRx Series: Devices & DNA conference on November 12, 2020, at 12:30 p.m. ET. A live webcast of the presentation will be available on Zimmer Biomet's Investor Relations website and will be archived for replay. Established in 1927 and based in Warsaw, Indiana, Zimmer Biomet is a leader in musculoskeletal healthcare, offering a range of orthopedic and surgical products. For more details, visit zimmerbiomet.com.
Zimmer Biomet has launched a multimedia campaign titled Don't Let Pain Gain on You to encourage individuals who have postponed joint replacement surgeries due to the COVID-19 pandemic to consult with healthcare professionals. A recent survey reveals that 48% of potential candidates delayed treatment, with 53% waiting over a year. The campaign seeks to empower these candidates, highlighting that 82% of patients who underwent surgery felt safe during the process. The initiative aims to address the increasing pain and mobility issues faced by those delaying surgery.
Zimmer Biomet Holdings (NYSE: ZBH) will host its third quarter earnings conference call on November 6, 2020, at 8:30 a.m. ET. A news release with detailed financial results will be available earlier that day at 6:30 a.m. ET. Investors can access the live webcast through the Investor Relations website. For those in the U.S. and Canada wishing to participate via phone, call (888) 312-9837 using conference ID 7278985. A digital recording will be accessible from November 6, 2020, to January 10, 2021.
Zimmer Biomet Holdings has declared a quarterly cash dividend of $0.24 per share for Q3 2020. This dividend will be payable on or about October 30, 2020 to stockholders who are on record as of the close of business on September 30, 2020. The commitment to returning value to shareholders reflects the company's confidence in its financial position and ongoing operations in the musculoskeletal healthcare sector.
Zimmer Biomet Holdings (NYSE: ZBH) announced that President and CEO Bryan Hanson and CFO Suky Upadhyay will present at the Morgan Stanley Virtual Global Healthcare Conference on September 15, 2020, at 2:00 p.m. ET. A live webcast will be available on the company’s Investor Relations website, with an archived replay option. Founded in 1927 and based in Warsaw, Indiana, Zimmer Biomet specializes in musculoskeletal healthcare, offering a variety of orthopedic and surgical products worldwide.
FAQ
What is the current stock price of Zimmer Biomet Holdings (ZBH)?
What is the market cap of Zimmer Biomet Holdings (ZBH)?
What does Zimmer Biomet do?
Where is Zimmer Biomet headquartered?
What are Zimmer Biomet's latest innovations?
What is Zimmer Biomet's focus on health equity?
How did Zimmer Biomet perform financially in the first quarter of 2024?
What are Zimmer Biomet's partnerships?
What is the ROSA® Robotics system?
What is the Community Centered Care (C3) framework?
What is Zimmer Biomet's role in pickleball?
How does Zimmer Biomet contribute to innovation in healthcare?
